Pharmaceutical governance system for costly drugs through human rights due diligence
Katrina Perehudoff co-authored a new publication in The BMJ examining how a human rights due diligence framework could strengthen pharmaceutical governance and improve access to costly new drugs.

Key messages
- A pharmaceutical governance system grounded in international human rights, particularly the right to health and access to drugs, could help achieve equitable access to costly drugs
- A human rights due diligence approach could be used to promote government compliance with human rights while working towards national and international legislation
- This approach could also be used to ensure corporate action to promote availability, accessibility, acceptability, and quality of drugs for rare diseases